Studie
CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, dubbelblind, placebokontrollerad trial.
In 365 older adults without dementia, high-dose DHA reached cerebrospinal fluid but did not improve cognition or brain structure over 24 months.
Denna fas IIa-studie testade högdos-DHA hos vuxna i åldern 55–80 år utan demens som hade ett lågt intag av DHA via kosten. Den 24 månader långa studien vid University of Southern California var randomiserad, dubbelblind och placebokontrollerad. Av 739 screenade personer randomiserades 365: 181 till LP-gruppen och 184 till gruppen utan LP. Mean age was 66.4 years, 58% of participants were female, 39% were Hispanic, and 47% carried APOE epsilon4. The supplied abstract does not state the DHA dose or fully reproduce the eligibility text, but it reports the main biochemical result. At six months, DHA increased the cerebrospinal-fluid DHA/arachidonic-acid ratio versus placebo by 0.19 (95% CI 0.16 to 0.21). This demonstrates central nervous system target engagement. It did not translate into detectable differences in cognition or brain structure over 24 months. The trial was funded by the National Institute on Aging and the ADDF. For people looking for dementia prevention or brain-ageing benefits, the key result is negative on clinical and structural outcomes despite a clear biomarker change.
High-dose DHA achieved CNS target engagement, but no differences in cognition or brain structure were observed over 24 months.
The positive result was a cerebrospinal-fluid biochemical ratio, while cognition and brain structure did not differ. The abstract does not state the DHA dose in the supplied text, and participants were selected for low dietary DHA intake.
Citerad av
1 encyklopediartiklar refererar till denna studie.